Akebia Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, AKBA, Akebia Therapeutics Inc, priceseries

Akebia Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
2.45
Close
2.53
High
2.57
Low
2.42
Previous Close
2.42
Daily Price Gain
0.11
YTD High
2.70
YTD High Date
Mar 3, 2022
YTD Low
1.71
YTD Low Date
Feb 14, 2022
YTD Price Change
0.08
YTD Gain
3.27%
52 Week High
4.33
52 Week High Date
Jun 28, 2021
52 Week Low
1.71
52 Week Low Date
Feb 14, 2022
52 Week Price Change
-0.80
52 Week Gain
-24.02%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 24. 2017
9.31
May 10. 2017
11.97
12 Trading Days
28.54%
Link
LONG
May 12. 2017
12.69
May 26. 2017
13.51
10 Trading Days
6.49%
Link
LONG
Jun 19. 2017
14.61
Jun 28. 2017
15.51
7 Trading Days
6.15%
Link
LONG
Aug 11. 2017
14.29
Oct 9. 2017
18.90
40 Trading Days
32.24%
Link
LONG
May 11. 2018
9.83
May 25. 2018
10.33
10 Trading Days
5.13%
Link
LONG
Dec 10. 2018
8.89
Dec 13. 2018
9.67
3 Trading Days
8.77%
Link
LONG
Feb 4. 2019
5.80
Mar 6. 2019
7.24
21 Trading Days
24.76%
Link
LONG
Mar 11. 2019
7.34
Mar 29. 2019
8.18
14 Trading Days
11.40%
Link
LONG
Aug 8. 2019
4.17
Aug 21. 2019
4.44
9 Trading Days
6.43%
Link
LONG
Sep 9. 2019
4.28
Sep 16. 2019
4.79
5 Trading Days
11.93%
Link
LONG
Nov 22. 2019
4.21
Dec 20. 2019
6.21
19 Trading Days
47.62%
Link
LONG
Jan 14. 2020
6.90
Jan 27. 2020
7.59
8 Trading Days
10.07%
Link
LONG
Feb 3. 2020
7.88
Feb 24. 2020
9.14
14 Trading Days
16.12%
Link
LONG
Mar 23. 2020
6.23
Apr 1. 2020
6.67
7 Trading Days
7.10%
Link
LONG
May 4. 2020
8.66
May 28. 2020
11.67
17 Trading Days
34.73%
Link
LONG
Oct 5. 2020
2.69
Oct 21. 2020
3.42
12 Trading Days
27.21%
Link
LONG
Nov 16. 2020
2.60
Dec 2. 2020
2.96
11 Trading Days
13.99%
Link
LONG
Feb 1. 2021
3.40
Feb 18. 2021
4.35
12 Trading Days
27.79%
Link
LONG
May 26. 2021
3.43
Jun 1. 2021
3.60
3 Trading Days
5.10%
Link
LONG
Oct 29. 2021
2.87
Nov 4. 2021
3.04
4 Trading Days
5.96%
Link
Company Information
Stock Symbol
AKBA
Exchange
NasdaqGM
Company URL
http://www.akebia.com
Company Phone
617-871-2098
CEO
John P. Butler
Headquarters
Massachusetts
Business Address
245 FIRST STREET, SUITE 1100, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001517022
About

Akebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease. Its lead product candidate, AKB-6548, is in a Phase 2b clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading